Clinical Trial: Evaluation of Targeted Radionuclide Therapy of Lu-177 PSMA in Patients With Compromised Renal and/or Bone Marrow Function

U.S., Sept. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07169825) titled 'Evaluation of Targeted Radionuclide Therapy of Lu-177 PSMA in Patients With Compromised Renal and/or Bone Marrow Function' on Sept. 05.

Brief Summary: To determine the dose of Pluvicto therapy absorbed in the tumors and organs of patients whose kidneys and/or bone marrow are not working properly.

Study Start Date: Feb. 13, 2026

Study Type: INTERVENTIONAL

Condition: Lu-177 PSMA

Intervention: DRUG: Lu-177

Given by IV

OTHER: SPECT

SPECT/CT

Recruitment Status: NOT_YET_RECRUITING

Sponsor: M.D. Anderson Cancer Center

Published by HT Digital Content Services with permission from Health Daily Digest....